Adenosine A2A receptor antagonists /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Chen, Jiang-Fan, Mori, Akihisa
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA : Academic Press, 2023.
Colección:International review of neurobiology ; v. 170.
Temas:
Adenosine > Antagonists > Therapeutic use.
Adenosine > Receptors.
Parkinson's disease > Treatment.
Neural receptors.
Neurobiology.
Ad�enosine > Antagonistes > Emploi en th�erapeutique.
Ad�enosine > R�ecepteurs.
Maladie de Parkinson > Traitement.
Neuror�ecepteurs.
Neurobiologie.
Electronic books.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front cover
  • Series page
  • Title page
  • Copyright
  • Contents
  • Contributors
  • Preface
  • Chapter One: A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists
  • 1 Introduction
  • 2 A2AAR agonists
  • 3 Positive allosteric enhancers (PAMs)
  • 4 A2AAR antagonists and inverse agonists
  • 5 Negative allosteric enhancers (NAMs)
  • 6 A2AAR partial agonists
  • 7 Conclusions
  • References
  • Chapter Two: Adenosine A2A receptor and glia
  • 1 Preface
  • 2 A2AR in astrocytes
  • 3 Astrocyte A2AR and Alzheimer's disease
  • 4 Astrocyte A2AR and PD
  • 5 A2AR and microglia
  • 6 Microglial A2A receptor and process retraction
  • 7 Microglial A2A receptor and neuroinflammation
  • 8 Microglial A2AR and AD
  • 9 Microglial adenosine A2AR and PD
  • 10 Microglial adenosine A2A receptor and stroke
  • 11 Microglial A2AR in other diseases
  • 12 Role of other microglial adenosine A1 and A3 receptors
  • 13 A2AR and oligodendrocytes
  • 14 Perspective
  • References
  • Chapter Three: The adenosine A2A receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling
  • 1 Introduction
  • 2 Expression of A2AR in the basal ganglia
  • 3 Functional selectivity and signalling of A2AR
  • 3.1 A2ARs as monomers
  • 3.2 A2ARs as heteromers
  • 3.3 A2AR-containing heteromers with relevance in basal ganglia circuits
  • 3.4 Multiple mechanisms of action of A2AR antagonists
  • 3.5 A2AR mediates the adenosine-dopamine functional interactions in the basal ganglia
  • 4 Heteromer expression in neurological diseases affecting the basal ganglia and in alterations of the reward circuits by drugs of abuse
  • 5 Concluding remarks
  • Conflict of interests
  • Author contribution
  • Funding
  • References
  • Chapter Four: How and why the adenosine A2A receptor became a target for Parkinson's disease therapy
  • How and why the adenosine A2A receptor became a target for Parkinson's disease therapy
  • 1 Introduction
  • 2 The relevance of the adenosinergic system and the A2A adenosine receptor
  • 3 Adenosine A2A receptors and motor function
  • 4 Adenosine A2A antagonists and dyskinesia
  • 5 Adenosine A2A antagonists and motor function in Parkinson's disease
  • 6 Other potential mechanisms of action of A2A adenosine antagonists
  • 7 Adenosine antagonists and non-motor symptoms of Parkinson's disease
  • 8 Exploring the future potential of adenosine A2A antagonists in Parkinson's disease
  • References
  • Chapter Five: Adenosine A2A antagonists and Parkinson's diseaseAdenosine A2A antagonists and Parkinson's disease
  • 1 Introduction
  • 2 Receptor agonists
  • 2.1 Dopamine receptor agonists
  • 2.1.1 Ergot dopamine agonists
  • 2.1.2 Non-ergot dopamine agonists
  • 3 Inverse agonists
  • 3.1 Serotonin receptor 2A inverse agonists
  • 4 Receptor antagonists
  • 4.1 Dopamine receptor antagonists
  • 4.2 NMDA receptor antagonists
  • 4.3 Acetylcholine receptor antagonists
  • 4.4 Adenosine receptor antagonists
  • Chapter six
  • Chapter seven
  • Chapter eight
  • Chapter nine
  • Chapter ten
  • Chapter eleven.

Ejemplares similares